The earnings call indicates strong progress in clinical trials, financial stability, and regulatory alignment, suggesting a positive trajectory for Taysha Gene Therapy. However, increased expenses and net loss present financial challenges.

Company Guidance

During Taysha Gene Therapy's second quarter 2025 earnings call, the company highlighted several key metrics and milestones for their TSHA-102 program aimed at treating Rett syndrome. Notably, the company achieved alignment with the FDA and Health Canada, enabling the initiation of their REVEAL pivotal trial. They plan to begin patient enrollment in the fourth quarter of 2025. The program's development is supported by promising clinical data, with a 100% response rate at the primary endpoint in the REVEAL Part A trials, demonstrating developmental milestone gains in all ten patients treated. Financially, Taysha reported a net loss of $26.9 million for the quarter, with $312.8 million in cash and equivalents, bolstered by a $230 million follow-on financing. The company expects this funding to extend their cash runway into 2028, supporting their ongoing efforts to bring TSHA-102 to market for the estimated 15,000 to 20,000 patients affected by Rett syndrome across the U.S., Europe, and the U.K.

FDA and Health Canada Alignment

Taysha Gene Therapy has obtained alignment with the FDA and Health Canada to proceed with initiating the REVEAL pivotal trial for TSHA-102, with site activation officially commenced.

Financial Strength

The company completed a public follow-on offering resulting in gross proceeds of $230 million, extending their cash runway into 2028.

Promising Clinical Data

All patients treated in Part A of the REVEAL trials gained or regained developmental milestones, corresponding to a 100% response rate for the pivotal trial’s primary endpoint.

Regulatory Progress

Commencement of site activation for pivotal trial with anticipated patient enrollment in Q4 2025.

Taysha Gene Therapies (TSHA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSHA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	-0.09 / -	-0.1	―	―	―
Aug 12, 2025	2025 (Q2)	-0.08 / -0.09	-0.09	0.00% (0.00)	―
May 15, 2025	2025 (Q1)	-0.09 / -0.08	-0.1	20.00% (+0.02)	―
Feb 26, 2025	2024 (Q4)	-0.08 / -0.07	0.255	-127.45% (-0.33)	―
Nov 13, 2024	2024 (Q3)	-0.09 / -0.10	-0.93	89.25% (+0.83)	―
Aug 12, 2024	2024 (Q2)	-0.16 / -0.09	-0.38	76.32% (+0.29)	―
May 14, 2024	2024 (Q1)	-0.11 / -0.10	-0.28	64.29% (+0.18)	―
Mar 19, 2024	2023 (Q4)	-0.11 / 0.26	-0.99	125.76% (+1.25)	―
Nov 14, 2023	2023 (Q3)	-0.17 / -0.93	-0.64	-45.31% (-0.29)	―
Aug 14, 2023	2023 (Q2)	-0.31 / -0.38	-0.84	54.76% (+0.46)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSHA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$2.76	$2.91	+5.43%
May 15, 2025	$2.37	$2.56	+8.02%
Feb 26, 2025	$1.70	$1.62	-4.71%
Nov 13, 2024	$2.21	$2.27	+2.71%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Taysha Gene Therapies (TSHA) report earnings?

Taysha Gene Therapies (TSHA) is schdueled to report earning on Nov 12, 2025, After Close (Confirmed).

What is Taysha Gene Therapies (TSHA) earnings time?

Taysha Gene Therapies (TSHA) earnings time is at Nov 12, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSHA EPS forecast?

TSHA EPS forecast for the fiscal quarter 2025 (Q3) is -0.09.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing